Table 2 Univariate and multivariable analysis for risk factors for progression in smoldering multiple myeloma
From: Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
Risk factor | Time to progression, months, median (95% CI) | Univariate modela | Multivariable modela,b | ||
---|---|---|---|---|---|
Hazard ratio (95% CI) | p | Hazard ratio (95% CI) | p | ||
Gender | |||||
• Male (n = 245) | 55.0 (41.0–109.8) | 0.95 (0.70–1.29) | 0.735 | NI | — |
• Female (n = 176) | 57.3 (43.3–73.2) | ||||
BMPC percentage | |||||
• >20% (n = 142) | 29.8 (15.9–35.9) | 2.79 (2.05–3.81) | <0.0001 | 2.28 (1.63–3.20) | <0.0001 |
• ≤20% (n = 279) | 83.1 (64.9–126.9) | ||||
Serum M-protein | |||||
• >2 g/dL (n = 195) | 38.3 (29.8–44.4) | 2.07 (1.51–2.85) | <0.0001 | 1.56 (1.11–2.20) | 0.010 |
• ≤2 g/dL (n = 222) | 109.8 (63.0–NR) | ||||
FLCr | |||||
• >20 (n = 125) | 30.8 (19.8–40.6) | 2.23 (1.63–3.04) | <0.0001 | 2.13 (1.55–2.93) | <0.0001 |
• ≤20 (n = 296) | 83.1 (63.0–109.8) | ||||
Immunoparesis | |||||
• Present (n = 262) | 50.6 (40.6–67.8) | 1.59 (1.07–2.45) | 0.022 | 1.01 (0.66–1.60) | 0.957 |
• Absent (n = 110) | 109.8 (58.1–NR) | ||||
M-protein isotype | |||||
• IgG (n = 319) | 57.3 (43.5–72.2) | 0.94 (0.67–1.37) | 0.761 | NI | — |
• Non-IgG (n = 102) | 62.1 (35.0–105.0) | ||||
• IgA (n = 83) | 65.1 (35.0–NR) | 1.04 (0.70–1.51) | 0.823 | NI | — |
• Non-IgA (n = 338) | 55.0 (43.4–69.1) |